Resmed highlights AI-driven CPAP tech, competitive bidding win and GLP-1 insights at J.P. Morgan Healthcare Conference 

SAN FRANCISCO – Resmed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Smart Comfort, will help improve both short- and long-term compliance with therapy. 

Resmed announced in late 2025 that the U.S. Food and Drug Administration (FDA) had cleared Smart Comfort. The technology will launch in a limited beta in early 2026 for new users of myAir paired with AirSense 11, with a broader rollout later this year. 

“So, we don’t have peer-reviewed, published evidence on this yet, but we will, and what we’re going to show is that actually having an AI algorithm that is sort of a sleep coach for you during your first periods of CPAP can really improve your – not just short term but long term – adherence with the therapy, which is a case of life and death,” he said. “That’s in the market.” 

According to Resmed, 95% of device users don’t adjust comfort settings like temperature and humidification—features that aren’t medical but impact adherence. 

Smart Comfort uses lifestyle-based questions – such as “Do you like to walk in the Swiss Alps, or do you like walks along the beach in Costa Rica?” – to recommend personalized settings. 

“(It) seems like a silly question, but we’re going to know if you like high humidity, high temperature or low humidity, cooler temperatures, and from that question can increase your adherence rate,” Farrell said. 

Resmed also has Dawn, a digital health concierge that guides users on sleep, nutrition, exercise, and overall wellness. 

Also heard from Resmed at the conference: 

Farrell characterized a decision by the Centers for Medicare & Medicaid Services (CMS) to not include CPAP devices and supplies in the next round of its competitive bidding program as a “great win for the industry.” 

“If you look over the last 15 years, the differential price between what the government is paying for our therapy and what private pay (is paying), 15 years ago, there was a big delta,” he said. “That's why they started the competitive bidding program. Now it's right at equilibrium. And so, there was no real need, economically to do it. And there were other DME products that maybe had a larger differential. And so, I think that's where Dr. Oz and CMS are focusing now on the differential in those other areas.” 

The company has now completed an online educational CME program to better educate primary care physicians about obstructive sleep apnea, with a focus on high-volume GLP-1 prescribers. 

"Seventy seven percent of them say, we’re going to change our protocols of how we deal with obstructive sleep apnea, who we refer to and how we refer to it,” Farrell said. 

Company officials continue to maintain that GLP-1s will not replace CPAP therapy on a large scale, now backed by three years of data on millions of patients using the weight loss drugs. 

“We are still seeing when you look at the data that at one year, the majority of patients are off of GLP-1 therapy,” said Carlos Nunez, chief medical officer. “So it's interesting to see that curve separate where we see patients coming off of GLP-1 therapy but staying good CPAP patients because they've realized, I may or may not be able to tolerate this drug or afford this drug, but I can't go another day without a good night sleep.”